Leveraging Bayesian Network meta-analysis to improve drug development

来源 :上海交通大学 | 被引量 : 0次 | 上传用户:ghanfeng
下载到本地 , 更方便阅读
声明 : 本文档内容版权归属内容提供方 , 如果您对本文有版权争议 , 可与客服联系进行内容授权或下架
论文部分内容阅读
  The extent of phase 3 failures contributes significantly to the increasing costs of drug development.
其他文献
Modern clinical research studies commonly acquire complementary multi-modal and multisource data for each patient in order to obtain a more accurate and rigorous assessment of the disease status and l
DNA methylation plays an important role in many biological processes and cancer progression.Recent studies have noticed that there are also differences in methylation variations in different groups ot
In clinical studies with time-to-event outcomes,the restricted mean survival time(RMST)has attracted substantial attention as a summary measurement for its straightforward clinical interpretation.
One great challenge of big data research is to efficiently and accurately identify the inherent complex network structure.
The constraints of high-dimensionality(HD)and positive-definiteness(PD)presents difficulties for modelling covariance matrix structures.
In this paper,we consider different score functions in order summarize certain characteristics for one and two sample ranking data sets.
会议
Aspergillus sp.,an endophytic fungus,isolated from roots of an antimony(Sb)tolerant plant(Hedysarum pallidum Desf),shows tolérance to high Sb concentration(500 mM).
Parameters in marginal structural Cox models can be estimated through an inverse probability of treatment and censoring(IPTC)weighted Cox partial likelihood.
In many applications,including disease early detection and prevention,and performance evaluation of airplanes and other durable products,we need to sequentially monitor the longitudinal pattern of cer
High-throughput biological data,such as microarray data and gene sequencing data,are plagued by unwanted variation – systematic errors introduced by variations in experimental conditions such as tempe